-+ 0.00%
-+ 0.00%
-+ 0.00%

Qlife Confirms Biomarker Testing Platform's Potential for New Therapeutic Area

MT Newswires·09/29/2026 07:53:59
Listen to the news
07:53 AM EDT, 09/29/2026 (MT Newswires) -- Qlife Holding (QLIFE.ST) completed a feasibility study aimed at demonstrating its Egoo platform's viability within a new therapeutic area that requires regular biomarker monitoring. The study, which was funded by a global pharmaceutical company, confirmed the biomarker testing platform's potential for decentralized monitoring of a clinically relevant biomarker in patients, according to a Tuesday release. The medical technology company and its pharmaceutical partner are evaluating possible next steps, which may include additional feasibility studies and a wider product development program.